Innovative instrument and software create revolutionary system to improve data, work-flow and results from in vivo cancer models
Princeton, NJ Biopticon today announced that it had met its first milestone for customer adoption of the revolutionary TumorImagerTM with the installation of in multiple systems at Merck sites Boston and Palo Alto. Previous placements were made at Johnson & Johnson’s Ortho Biotech Oncology R&D unit, AstraZeneca’s MedImmune unit, Covidien Imaging, Bayer and the Simon Cancer Center at Indiana University.
“We are extremely pleased to have so many major pharmaceutical customers recognize the value this system brings to their preclinical oncology studies. Several of these groups have shared their data with us showing the improved statistics give them greater confidence that they are getting meaningful results, in a shorter time along with greater sensitivity to drug response” said Jim Patterson, Biopticon’s Vice President of Sales and Marketing. “These customers form the core of our user advisory team which provides us with constant feedback on how to enhance our system to better meet their needs. Their input will be incorporated into the next release of TumorManagerTM due to be released in early 2012. With this successful entry into the market we believe that this transformational technology is poised for adoption by pharmaceutical, biotechnology, academic and contract research groups worldwide.”
Dr. Cem Girit, Founder and President, added “as we see our imagining technology gaining acceptance for preclinical oncology applications we can now continue development of systems for arthritis research.”